83 FR 53485 - Agency Information Collection Activities; Proposed Collection; Comment Request; National Panel of Tobacco Consumer Studies
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 83, Issue 205 (October 23, 2018)
Food and Drug Administration
Federal Register Volume 83, Issue 205 (October 23, 2018)
| Page Range | 53485-53487 | |
| FR Document | 2018-23060 |
[Federal Register Volume 83, Number 205 (Tuesday, October 23, 2018)] [Notices] [Pages 53485-53487] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-23060] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2014-N-1533] Agency Information Collection Activities; Proposed Collection; Comment Request; National Panel of Tobacco Consumer Studies AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the National Panel of Tobacco Consumer Studies. DATES: Submit either electronic or written comments on the collection of information by December 24, 2018. ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before December 24, 2018. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of December 24, 2018. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. Electronic Submissions Submit electronic comments in the following way:Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ``Written/Paper Submissions'' and ``Instructions''). Written/Paper Submissions Submit written/paper submissions as follows: Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ``Instructions.'' Instructions: All submissions received must include the Docket No. FDA-2014-N-1533 for ``Agency Information Collection Activities; Proposed Collection; Comment Request; National Panel of Tobacco Consumer Studies.'' Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. Confidential Submissions--To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available [[Page 53486]] for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ``confidential.'' Any information marked as ``confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.thefederalregister.org/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ``Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-8867, [email protected]. SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. National Panel of Tobacco Consumer Studies OMB Control Number 0910-0815--Extension I. Background FDA's Center for Tobacco Products (CTP) established a national, primarily web-based panel of about 4,000 tobacco users. The panel includes individuals who can participate in up to eight studies over a 3-year period to assess consumers' responses to tobacco marketing, warning statements, product labels, and other communications about tobacco products. CTP established the panel of consumers because currently existing panels have a number of significant limitations. First, many existing consumer panels are drawn from convenience samples that limit the generalizability of study findings (Ref. 1). Second, although at least two probability-based panels of consumers exist in the United States, there is a concern that responses to the studies using tobacco users in these panels may be biased due to panel conditioning effects (Refs. 2 and 3). That is, consumers in these panels complete surveys so frequently that their responses may not adequately represent the population as a whole. Panel conditioning has been associated with repeated measurement on the same topic (Ref. 4), panel tenure (Ref. 2), and frequency of the survey request (Ref. 3). This issue is of particular concern for tobacco users who represent a minority of the members in the panels, and so may be more likely to be selected for participation in experiments and/or surveys related to tobacco products. Third, a key benefit of the web panel approach is that the surveys can include multimedia, such as images of tobacco product packages, tobacco advertising, new and existing warning statements and labels, and potential reduced harm claims in the form of labels and print advertisements. Establishing a primarily web-based panel of tobacco users through in-person probability-based recruitment of eligible adults and limiting the number of times individuals participate in tobacco-related studies will result in nationally representative and unbiased data collection on matters of importance for FDA. With this submission, FDA seeks an extension on the currently approved information collection request from OMB for remaining planned panel maintenance and replenishment activities for the National Panel of Tobacco Consumer Studies. Data collection activities will involve mail and in-person household screening, in-person recruitment of tobacco users, enrollment of selected household members, and administration of a baseline survey, following all required informed consent procedures for panel members. Panel members will be asked to participate in up to eight experimental and observational studies over the 3-year panel commitment period. The first of these panel studies, Study A ``Brands and Purchasing Behavior,'' was included in the currently approved information collection request; approval for Studies B, C, and D are included in this extension request. The first of these panel studies, Study A ``Brands and Purchasing Behavior,'' was included in the currently approved information collection request. Study B ``Coupons and Free Samples,'' Study C ``Consumer Perceptions of Product Standards,'' and Study D ``Hypothetical Purchasing of Tobacco Products'' are included in this request for extension. Study B will be an observational study offered to all panelists that will provide a more in-depth examination of tobacco product promotions, namely free samples and coupons, after the ban on distribution of free samples of tobacco products (with the exception of certain smokeless tobacco exemptions) that went into effect when FDA finalized the ``Deeming Rule'' on August 8, 2016 (published May 10, 2016 (81 FR 28973)) that extended FDA's regulatory authority to all tobacco products. Study C will be an experimental study examining how a hypothetical tobacco product standard may impact consumers' perceptions, attitudes, and tobacco use behavioral intentions. Study D will be an experimental study using behavioral economic methods that seeks to understand how the availability or lack of availability of menthol cigarettes potentially impacts adult cigarette smokers' product purchasing choices. The current request also seeks approval to update the estimated burden for an additional year of panel replenishment. The overall purpose of the data collection is to collect information from [[Page 53487]] a national sample of tobacco users to provide data that may be used to develop and support FDA's policies related to tobacco products, including their labels, labeling, and advertising. The target population for the panel is tobacco users aged 18 years and older in housing units and in noninstitutionalized group quarters in the 50 states and the District of Columbia. A stratified four-stage sample design was used, with a goal of recruiting 4,000 adult tobacco users into the sample panel. The sample is designed to allow in-depth analysis of subgroups of interest and to the extent possible, provide insight into tobacco users more generally. Replenishment will be conducted to maintain the panel with a constant number of members following existing panel recruitment and enrollment methods. FDA estimates the burden of this collection of information as follows: Table 1--Estimated Annual Reporting Burden 1 ---------------------------------------------------------------------------------------------------------------- No. of No. of responses per Total annual Average burden Total hours 3 Activity/respondent respondents respondent 2 responses 3 per response ---------------------------------------------------------------------------------------------------------------- Household Screening 35,885 0.33 11,842 0.13 (8 minutes). 1,539 Respondent 4. Panel Member Enrollment 4,000 0.33 1,320 0.25 (15 minutes) 330 Survey. Panel Member Baseline Survey. .............. 0.33 1,320 0.25 (15 minutes) 330 Study A...................... .............. 0.33 1,320 0.33 (20 minutes) 436 Study B...................... .............. 0.33 1,320 0.33 (20 minutes) 436 Study C...................... .............. 0.33 1,320 0.33 (20 minutes) 436 Study D...................... .............. 0.33 1,320 0.33 (20 minutes) 436 Panel Replenishment Household 30,855 0.33 10,182 0.13 (8 minutes). 1,324 Screening Respondent. Panel Replenishment 4,200 0.33 1,386 0.25 (15 minutes) 347 Enrollment Survey 5. Panel Replenishment Baseline .............. 0.33 1,386 0.25 (15 minutes) 347 Survey 5. ---------------------------------------------------------------------------------- Total.................... .............. .............. .............. ................. 5,961 ---------------------------------------------------------------------------------------------------------------- 1 There are no capital costs or operating and maintenance costs associated with this collection of information. 2 Assumes respondents will participate once over a 3-year period, or 0.33 responses annually. 3 Amounts are rounded to the nearest whole number. 4 Includes both mail and field screening. 5 Assumes 1,400 additional panel members will be recruited annually (4,200 total) as part of the panel replenishment effort. FDA's burden estimate is based on timed-readings of each instrument, including the mail and field screeners, enrollment survey, baseline survey, and Study A-D questionnaires. Of the total screening respondents, we expect 25 percent will respond only in the mail screening (household deemed ineligible), 65 percent will respond only in the field screening (mail screening nonrespondents), and the remaining 10 percent will respond in both the mail screening and the field screening. The latter includes eligible households from the mail screening that are subsequently field-screened to sample the panel member, and the 10 percent quality control sample of households whose mail screening ineligibility is verified through in-person screening. This assumes an estimated 10,285 household screening respondent during yearly panel replenishment (30,855 total). Replenishment panel members replace original panel members and become part of the 4,000-member panel that receives experimental/observational and panel maintenance surveys. This extension reflects an increase of 1,527 hours due to an additional year of panel replenishment and fielding of Studies B, C, and D. The estimated burden assumes 10,285 household screening respondents during yearly panel replenishment (30,855 total) and 1,400 additional panel members recruited annually (4,200 total) as part of the panel replenishment effort. II. References The following references are on display at the Dockets Management Staff (see ADDRESSES) and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they are also available electronically at https://www.regulations.gov. FDA has verified the website addresses, as of the date this document publishes in the Federal Register, but websites are subject to change over time. 1. Baker, R., Blumberg, S., Brick, M., et al., 2010, ``American Association for Public Opinion Research Report on Online Panels.'' Public Opinion Quarterly, 74(4), pp. 711-781. 2. Coen, T., Lorch, J. and Piekarski, L., 2005, ``The Effects of Survey Frequency on Panelists' Responses. Worldwide Panel Research: Developments and Progress,'' Amsterdam, European Society for Opinion and Marketing Research. 3. Nancarrow, C. and Catwright, T., 2007, ``Online Access Panels and Tracking Research, The Conditioning Issue,'' International Journal of Market Research, 49(5), pp. 435-447. 4. Kruse, Y., Callegaro, M., Dennis, J. M., et al., 2009, Panel Conditioning and Attrition in the AP-Yahoo! News Election Panel Study, Paper presented at the American Association for Public Opinion Research 64th Annual Conference. Dated: October 17, 2018. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2018-23060 Filed 10-22-18; 8:45 am] BILLING CODE 4164-01-P
![Federal Register / Vol. 83, No. 205 / Tuesday, October 23, 2018 / Notices 53485
VI. Duration of the OCT 510(k) Pilot GuidanceDocuments/UCM284443. comment will be made public, you are
Program Dated: October 17, 2018. solely responsible for ensuring that your
FDA intends to accept requests for Leslie Kux, comment does not include any
participation in the voluntary OCT Associate Commissioner for Policy.
confidential information that you or a
510(k) Pilot Program from the date of third party may not wish to be posted,
[FR Doc. 2018–23059 Filed 10–22–18; 8:45 am]
publication in the Federal Register such as medical information, your or
BILLING CODE 4164–01–P
through one year, or until the time when anyone else’s Social Security number, or
a total of nine participants have been confidential business information, such
enrolled. as a manufacturing process. Please note
DEPARTMENT OF HEALTH AND
that if you include your name, contact
VII. Paperwork Reduction Act of 1995 HUMAN SERVICES
information, or other information that
This notice refers to previously Food and Drug Administration identifies you in the body of your
approved collections of information comments, that information will be
[Docket No. FDA–2014–N–1533] posted on https://www.regulations.gov.
found in FDA regulations and guidance.
These collections of information are • If you want to submit a comment
Agency Information Collection with confidential information that you
subject to review by the Office of Activities; Proposed Collection;
Management and Budget (OMB) under do not wish to be made available to the
Comment Request; National Panel of public, submit the comment as a
the Paperwork Reduction Act of 1995 Tobacco Consumer Studies
(44 U.S.C. 3501–3520). The collections written/paper submission and in the
of information in 21 CFR part 807, AGENCY: Food and Drug Administration, manner detailed (see ‘‘Written/Paper
subpart E have been approved under HHS. Submissions’’ and ‘‘Instructions’’).
OMB control number 0910–0120. The ACTION: Notice. Written/Paper Submissions
collections of information in ‘‘Requests Submit written/paper submissions as
for Feedback on Medical Device SUMMARY: The Food and Drug
Administration (FDA, Agency, or we) is follows:
Submissions: The Pre-Submission • Mail/Hand delivery/Courier (for
Program and Meetings with Food and announcing an opportunity for public
written/paper submissions): Dockets
Drug Administration Staff’’ have been comment on the proposed collection of
Management Staff (HFA–305), Food and
approved under OMB control number certain information by the Agency.
Drug Administration, 5630 Fishers
0910–0756. Under the Paperwork Reduction Act of
Lane, Rm. 1061, Rockville, MD 20852.
1995 (PRA), Federal Agencies are • For written/paper comments
VIII. References required to publish notice in the submitted to the Dockets Management
The following references are on Federal Register concerning each Staff, FDA will post your comment, as
display at the Dockets Management Staff proposed collection of information, well as any attachments, except for
(HFA–305), Food and Drug including each proposed extension of an information submitted, marked and
Administration, 5630 Fishers Lane, Rm. existing collection of information, and identified, as confidential, if submitted
1061, Rockville, MD 20852, and are to allow 60 days for public comment in as detailed in ‘‘Instructions.’’
available for viewing by interested response to the notice. This notice Instructions: All submissions received
persons between 9 a.m. and 4 p.m., solicits comments on the National Panel must include the Docket No. FDA–
Monday through Friday; they are also of Tobacco Consumer Studies. 2014–N–1533 for ‘‘Agency Information
available electronically at https:// DATES: Submit either electronic or Collection Activities; Proposed
www.regulations.gov. FDA has verified written comments on the collection of Collection; Comment Request; National
the website addresses, as of the date this information by December 24, 2018. Panel of Tobacco Consumer Studies.’’
document publishes in the Federal ADDRESSES: You may submit comments Received comments, those filed in a
Register, but websites are subject to as follows. Please note that late, timely manner (see ADDRESSES), will be
change over time. untimely filed comments will not be placed in the docket and, except for
1. MDUFA IV Commitment Letter, available considered. Electronic comments must those submitted as ‘‘Confidential
at https://www.fda.gov/downloads/ be submitted on or before December 24, Submissions,’’ publicly viewable at
ForIndustry/UserFees/ 2018. The https://www.regulations.gov https://www.regulations.gov or at the
MedicalDeviceUserFee/UCM535548.pdf.
2. FDA Guidance for Industry and FDA Staff
electronic filing system will accept Dockets Management Staff between 9
‘‘Requests for Feedback on Medical comments until 11:59 p.m. Eastern Time a.m. and 4 p.m., Monday through
Device Submissions: The Pre- at the end of December 24, 2018. Friday.
Submission Program and Meetings with Comments received by mail/hand • Confidential Submissions—To
Food and Drug Administration Staff’’ delivery/courier (for written/paper submit a comment with confidential
dated September 29, 2017, available at submissions) will be considered timely information that you do not wish to be
https://www.fda.gov/MedicalDevices/ if they are postmarked or the delivery made publicly available, submit your
DeviceRegulationandGuidance/ comments only as a written/paper
GuidanceDocuments/UCM311176.
service acceptance receipt is on or
3. FDA Guidance for Industry and FDA Staff before that date. submission. You should submit two
‘‘Refuse to Accept Policy for 510(k)s’’ copies total. One copy will include the
Electronic Submissions information you claim to be confidential
dated January 30, 2018, available at
https://www.fda.gov/MedicalDevices/ Submit electronic comments in the with a heading or cover note that states
DeviceRegulationandGuidance/ following way: ‘‘THIS DOCUMENT CONTAINS
khammond on DSK30JT082PROD with NOTICES
GuidanceDocuments/UCM315014. • Federal eRulemaking Portal: CONFIDENTIAL INFORMATION.’’ The
4. FDA Guidance for Industry and FDA Staff https://www.regulations.gov. Follow the Agency will review this copy, including
‘‘The 510(k) Program: Evaluating instructions for submitting comments. the claimed confidential information, in
Substantial Equivalence in Premarket
Notifications [510(k)]’’ dated July 28, Comments submitted electronically, its consideration of comments. The
2014, available at: https://www.fda.gov/ including attachments, to https:// second copy, which will have the
MedicalDevices/ www.regulations.gov will be posted to claimed confidential information
DeviceRegulationandGuidance/ the docket unchanged. Because your redacted/blacked out, will be available
VerDate Sep<11>2014 20:20 Oct 22, 2018 Jkt 247001 PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 E:\FR\FM\23OCN1.SGM 23OCN1](https://thefederalregister.org/doc/83_FR_53690/page/1.svg)
![Federal Register / Vol. 83, No. 205 / Tuesday, October 23, 2018 / Notices 53487
a national sample of tobacco users to noninstitutionalized group quarters in possible, provide insight into tobacco
provide data that may be used to the 50 states and the District of users more generally. Replenishment
develop and support FDA’s policies Columbia. A stratified four-stage sample will be conducted to maintain the panel
related to tobacco products, including design was used, with a goal of with a constant number of members
their labels, labeling, and advertising. recruiting 4,000 adult tobacco users into following existing panel recruitment
The target population for the panel is the sample panel. The sample is and enrollment methods.
tobacco users aged 18 years and older in designed to allow in-depth analysis of FDA estimates the burden of this
housing units and in subgroups of interest and to the extent collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
No. of
No. of Total annual
Activity/respondent responses per Average burden per response Total hours 3
respondents responses 3
respondent 2
Household Screening Respondent 4 ....... 35,885 0.33 11,842 0.13 (8 minutes) ......................... 1,539
Panel Member Enrollment Survey .......... 4,000 0.33 1,320 0.25 (15 minutes) ....................... 330
Panel Member Baseline Survey .............. ........................ 0.33 1,320 0.25 (15 minutes) ....................... 330
Study A .................................................... ........................ 0.33 1,320 0.33 (20 minutes) ....................... 436
Study B .................................................... ........................ 0.33 1,320 0.33 (20 minutes) ....................... 436
Study C .................................................... ........................ 0.33 1,320 0.33 (20 minutes) ....................... 436
Study D .................................................... ........................ 0.33 1,320 0.33 (20 minutes) ....................... 436
Panel Replenishment Household 30,855 0.33 10,182 0.13 (8 minutes) ......................... 1,324
Screening Respondent.
Panel Replenishment Enrollment Sur- 4,200 0.33 1,386 0.25 (15 minutes) ....................... 347
vey 5.
Panel Replenishment Baseline Survey 5 ........................ 0.33 1,386 0.25 (15 minutes) ....................... 347
Total ................................................. ........................ ........................ ........................ .................................................... 5,961
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
2 Assumes respondents will participate once over a 3-year period, or 0.33 responses annually.
3 Amounts are rounded to the nearest whole number.
4 Includes both mail and field screening.
5 Assumes 1,400 additional panel members will be recruited annually (4,200 total) as part of the panel replenishment effort.
FDA’s burden estimate is based on additional panel members recruited the American Association for Public
timed-readings of each instrument, annually (4,200 total) as part of the Opinion Research 64th Annual
including the mail and field screeners, panel replenishment effort. Conference.
enrollment survey, baseline survey, and Dated: October 17, 2018.
II. References
Study A–D questionnaires. Of the total Leslie Kux,
screening respondents, we expect 25 The following references are on Associate Commissioner for Policy.
percent will respond only in the mail display at the Dockets Management Staff
[FR Doc. 2018–23060 Filed 10–22–18; 8:45 am]
screening (household deemed (see ADDRESSES) and are available for
BILLING CODE 4164–01–P
ineligible), 65 percent will respond only viewing by interested persons between
in the field screening (mail screening 9 a.m. and 4 p.m., Monday through
nonrespondents), and the remaining 10 Friday; they are also available DEPARTMENT OF HEALTH AND
percent will respond in both the mail electronically at https:// HUMAN SERVICES
screening and the field screening. The www.regulations.gov. FDA has verified
latter includes eligible households from the website addresses, as of the date this Health Resources and Services
the mail screening that are subsequently document publishes in the Federal Administration
field-screened to sample the panel Register, but websites are subject to
member, and the 10 percent quality change over time. Agency Information Collection
control sample of households whose 1. Baker, R., Blumberg, S., Brick, M., et al., Activities: Proposed Collection: Public
mail screening ineligibility is verified 2010, ‘‘American Association for Public Comment Request; Information
through in-person screening. This Opinion Research Report on Online Collection Request Title: Children’s
assumes an estimated 10,285 household Panels.’’ Public Opinion Quarterly, 74(4), Graduate Medical Education Quality
pp. 711–781. Bonus System (QBS) Initiative
screening respondent during yearly 2. Coen, T., Lorch, J. and Piekarski, L., 2005,
panel replenishment (30,855 total). Response Form, OMB No. 0906–xxxx–
‘‘The Effects of Survey Frequency on New
Replenishment panel members replace Panelists’ Responses. Worldwide Panel
original panel members and become Research: Developments and Progress,’’ AGENCY: Health Resources and Services
part of the 4,000-member panel that Amsterdam, European Society for Administration (HRSA), Department of
receives experimental/observational and Opinion and Marketing Research. Health and Human Services (HHS).
panel maintenance surveys. This 3. Nancarrow, C. and Catwright, T., 2007,
khammond on DSK30JT082PROD with NOTICES
‘‘Online Access Panels and Tracking ACTION: Notice.
extension reflects an increase of 1,527
hours due to an additional year of panel Research, The Conditioning Issue,’’
SUMMARY: In compliance with the
International Journal of Market
replenishment and fielding of Studies B, Research, 49(5), pp. 435–447. requirement for opportunity for public
C, and D. The estimated burden assumes 4. Kruse, Y., Callegaro, M., Dennis, J. M., et comment on proposed data collection
10,285 household screening al., 2009, Panel Conditioning and projects of the Paperwork Reduction Act
respondents during yearly panel Attrition in the AP-Yahoo! News of 1995, HRSA announces plans to
replenishment (30,855 total) and 1,400 Election Panel Study, Paper presented at submit an Information Collection
VerDate Sep<11>2014 20:20 Oct 22, 2018 Jkt 247001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\23OCN1.SGM 23OCN1](https://thefederalregister.org/doc/83_FR_53690/page/3.svg)
Document Created: 2018-10-23 04:14:31
Document Modified: 2018-10-23 04:14:31
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Dates | Submit either electronic or written comments on the collection of information by December 24, 2018. | |
| Contact | Amber Sanford, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-8867, [email protected] | |
| FR Citation | 83 FR 53485 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR